The use of monoclonal antibodies to deliver radioactive isotopes directly to tumor cells has become a promising strategy to enhance the antitumor effects of native monoclonal antibodies. In this article, we summarize the role of radioimmunotherapy in the treatment of leukemia.
Methods
The authors reviewed the published clinical trials of radioimmunotherapy in acute leukemia.
Results
Radioimmunoconjugates that emit β-particles, such as 131I-anti-CD33, 90Y-anti-CD33, 131I-anti-CD45, and 188Re-anti-CD66c, deliver significant doses of radiation to the bone marrow and may be particularly effective when used as part of a conditioning regimen for hematopoietic stem cell transplantation. Radioimmunoconjugates that emit short-ranged a-particles, such as 213Bi-anti-CD33, are better suited for the treatment of low-volume or residual disease.
Conclusions
Radiolabeled antibodies can be administered safely to patients with advanced leukemias and have significant antileukemic activity. Radiolabeled antibodies can potentially intensify the antileukemic effects of conditioning regimens when used in conjunction with hematopoietic stem cell transplantation. Whether or not radiolabeled antibodies improve the outcome of patients with leukemia remains to be demonstrated by randomized studies.
References
1.
CassilethP.A., HarringtonD.P., AppelbaumF.R.. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.N Engl J Med.1998; 339: 1649–1656.
OsterborgA., DyerM.J., BunjesD.. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.J Clin Oncol.1997; 15: 1567–1574.
5.
JurcicJ.G., DeBlasioT., DumontL.. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.Clin Cancer Res.2000; 6: 372–380.
6.
CaronP.C., JurcicJ.G., ScottA.M.. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.Blood.1994; 83: 1760–1768.
7.
CaronP.C., DumontL., ScheinbergD.A.. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.Clin Cancer Res.1998; 4: 1421–1428.
8.
FeldmanE., KalaycioM., SchulmanP.. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): preliminary report of a phase II study.Proc Annu Meet Am Soc Clin Oncol.1999; 12. Abstract.
9.
SieversE.L., LarsonR.A., StadtmauerE.A.. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.J Clin Oncol.2001; 19: 3244–3254.
10.
KreitmanR.J., WilsonW.H., BergeronK.. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.N Engl J Med.2001; 345: 241–247.
11.
SchwartzM.A., LovettD.R., RednerA.. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.J Clin Oncol.1993; 11: 294–303.
JurcicJ.G., CaronP.C., MillerWHJr. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.Leukemia.1995; 9: 244–248.
14.
JurcicJ.G., DivgiC.C.R., McDevittM.R.. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia.Proc Annu Meet Am Soc Clin Oncol.2000; 19: 24. Abstract.
15.
JurcicJ.G., McDevittM.R., SgourosG.. Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213-HuM195 (anti-CD33).Proc Annu Meet Am Soc Clin Oncol.1999; 18: 22. Abstract.
16.
AppelbaumF.R., MatthewsD.C., EaryJ.F.. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.Transplantation.1992; 54: 829–833.
17.
MatthewsD.C., AppelbaumF.R., EaryJ.F.. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.Blood.1999; 94: 1237–1247.
18.
MatthewsD.C., AppelbaumF.R., EaryJ.F.. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque.Blood.1991; 78: 1864–1874.
19.
MatthewsD.C., AppelbaumF.R., EaryJ.F.. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission.Blood.1996; 88: 556. Abstract.
20.
SeitzU., NeumaierB., GlattingG.. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.Eur J Nucl Med.1999; 26: 1265–1273.
21.
KotzerkeJ., GlattingG., SeitzU.. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.J Nucl Med.2000; 41: 531–537.
22.
BunjesD., BuchmannI., DunckerC.. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.Blood.2001; 98: 565–572.
23.
WaldmannT.A., WhiteJ.D., CarrasquilloJ.A.. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.Blood.1995; 86: 4063–4075.
AndrewsR.G., Torok-StorbB., BernsteinI.D.. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies.Blood.1983; 62: 124–132.
26.
GriffinJ.D., LinchD., SabbathK. etc. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.Leuk Res.1984; 8: 521–534.
27.
TanimotoM., ScheinbergD.A., Cordon-CardoC.. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.Leukemia.1989; 3: 339–348.
28.
CoM.S., AvdalovicN.M., CaronP.C.. Chimeric and humanized antibodies with specificity for the CD33 antigen.J Immunol.1992; 148: 1149–1154.
29.
ScheinbergD.A., TanimotoM., McKenzieS.. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia.Leukemia.1989; 3: 440–445.
30.
CaronP.C., CoM.S., BullM.K.. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.Cancer Res.1992; 52: 6761–6767.
31.
RuffnerK.L., MatthewsD.C.. Current uses of monoclonal antibodies in the treatment of acute leukemia.Semin Oncol.2000; 27: 531–539.
32.
MatthewsD.C.. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.Leukemia.1998; 12(suppl 1): S33–S36.
33.
NikulaT.K., BocchiaM., CurcioM.J.. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity.Mol Immunol.1995; 32: 865–872.
34.
ZalutskyM.R., McLendonR.E., GargP.K.. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.Cancer Res.1994; 54: 4719–4725.
35.
KennelS.J., BollR., StabinM.. Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi.Br J Cancer.1999; 80: 175–184.
36.
McDevittM.R., BarendswaardE., MaD.. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.Cancer Res.2000; 60: 6095–6100.
SgourosG., BallangrudA.M., JurcicJ.G.. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.J Nucl Med.1999; 40: 1935–1946.
